Mental Health Clinical Trials Market Size, Share & Trends Analysis Report by Phase, By Study Design, By Sponsor, By Disorder, By Region, And Segment Forecasts, 2022 To 2030

Industry Insights

The global mental health clinical trials market is anticipated to reflect a substantial growth rate across the forecast period. The key factors contributing to the growth of the market includes the increasing prevalence of mental health disorders, rising awareness of mental health diseases among the people, and increasing funding by government institutions, industry and hospital & universities.  Mental disorders involve considerable disturbances in emotional regulation, thinking, or behavior. According to a recent report by WHO, in 2022, 1 in every 8 people around the globe with a mental disorder. In 2019, 970 million people around the globe were living with a mental disorder and most common disorders are depression & anxiety.

The Covid-19 pandemic increase the prevalence of anxiety & depression globally by 25% according to a scientific report by WHO. Major factor includes stress caused by the social isolation during the pandemic. Fear of infection, suffering and death for oneself and for loved ones, loneliness, financial worries and grief after bereavement are all leads to depression and anxiety. However, governments are spending on average just 2% of their health budgets on mental health according to a recent mental health atlas by WHO.  

Based on disorders, anxiety segment has held a substantial share in the mental health clinical trials market. The anxiety disorders are characterized by worry, excessive fear and related behavioral disturbances. In 2019 according to WHO report, 301.0 million people have anxiety disorder and among them 58.0 million are adolescents & children. There are different types of anxiety disorders such as social anxiety disorder, separation anxiety disorder, panic disorder and generalized anxiety disorder.

North America is anticipated to hold the highest market share over the forecast period owing to factors such as increase in R&D investments, favorable government support and rise in adoption of new technologies in clinical trials. According to clinicaltrials.org, the region accounts 52% of registered depression clinical trials from 2019 to 2021. Furthermore, the proportion of trials in the region is increased from 45.9% to 50.9% from 2019 to 2021.

The key global industry players across the mental health clinical trials market include ICON PLC, Eli Lilly and Company, Caidya, Syneous Health, Novo Nordisk, Pharmaceutical Product Development, LLC, Parexel International Corporation, Corcept, LabCorp Drug Development and IQVIA.